L-XYLOSE

Registered in Wenjiang, Chengdu in 2005, AstaTech (Chengdu)Biopharmaceutical Corp. (“AstaTech”) was transformed from AstaTech (Chengdu)Pharmaceutical Company Limited that was established in 2000 in Chengdu.AstaTech was a wholly owned subsidiary of AstaTech Inc. in USA founded by Mr. PengGuo until 2012. AstaTech is a high-tech enterprise dedicated to CRO, CDMO,CMO,CMC and Process Safety Evaluation services for global pharmaceutical companies in small molecule drug intermediates. AstaTech has 12000-square-meter R&D labs and a kilo laboratory, with close to 340 employees, including more than 200 chemists, among which 18 are Ph.Ds. After nearly 20 years of development, AstaTech has provided thousands of worldwide customers with advanced API intermediates from Pre-clinic stage scale. Phase I, Phase II ,Phase III to Commercial scale and tens of thousands of novel advanced intermediates for drug discovery; AstaTech has established a full-fledged production system which caters to small-scale, pilot-scale and commercial manufacturing; process R&D teams for API and special chemicals; with ISO9001 and ICHQ7 Quality Management System,ISO14001 International Environmental Management Certification System,OHSAS18001 Occupational Health Management System and GB/T29490-2013 Enterprise Intellectual property Management System. AstaTech has filed 127 patent applications (among which 98 are invention patents) and 72 patents have been granted. AstaTech has more than 1000 global customers, including the top 30 global pharmaceutical companies in Europe, the U.S, Canada, Japan, Korea, India, China and other countries. To provide reliable CDMO services to customers in a long term, AstaTech has established offices in the U.S and India and multiple manufacturing sites in China, including Guang’an , Yibin Site in Sichuan and Changshou Site in Chongqing, which will be ready to operate in 2022. AstaTech has been granted as National High-tech Enterprise, Innovation & PracticeBase for Postdocto